NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 1.7% – Here’s What Happened

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)’s share price traded down 1.7% on Wednesday . The company traded as low as $1.15 and last traded at $1.17. 44,689 shares changed hands during trading, a decline of 73% from the average session volume of 163,478 shares. The stock had previously closed at $1.19.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reaffirmed a “hold” rating on shares of NeuroSense Therapeutics in a report on Monday, December 16th.

NeuroSense Therapeutics Price Performance

The company has a 50 day simple moving average of $1.12 and a 200-day simple moving average of $1.07. The stock has a market capitalization of $15.86 million, a P/E ratio of -1.81 and a beta of 1.27.

NeuroSense Therapeutics (NASDAQ:NRSN) last announced its quarterly earnings data on Wednesday, December 18th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in NeuroSense Therapeutics stock. XTX Topco Ltd grew its stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) by 40.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,996 shares of the company’s stock after acquiring an additional 13,346 shares during the period. XTX Topco Ltd owned 0.34% of NeuroSense Therapeutics worth $58,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.